Alcon Hits 175 Million IOL Implants, Highlighting PanOptix Pro and Vivity Growth
Event summary
- Alcon has implanted over 175 million intraocular lenses (IOLs) globally, with 6 million being presbyopia-correcting IOLs (PCIOLs).
- PanOptix trifocal IOL has surpassed 4 million implants worldwide, with 99% patient satisfaction.
- PanOptix Pro, launched in 2025, offers 94% light utilization and reduced scatter, enhancing image contrast.
- Vivity, a non-diffractive extended depth of focus (EDOF) IOL, has surpassed 2 million implants.
The big picture
Alcon's achievement of 175 million IOL implants underscores its dominance in the eye care sector, particularly in presbyopia-correcting lenses. The company's continuous innovation, from PanOptix to Vivity and now PanOptix Pro, aligns with the industry's shift towards advanced visual solutions that reduce dependency on glasses. With a strong portfolio and high patient satisfaction, Alcon is well-positioned to capitalize on the growing demand for premium IOLs.
What we're watching
- Product Innovation
- The pace at which Alcon introduces new IOL technologies, particularly PanOptix Pro and Vivity, will determine its ability to maintain market leadership.
- Regulatory Approvals
- Alcon's plans to launch new IOL technologies later in 2026 hinge on pending regulatory approvals, which could impact its growth trajectory.
- Market Expansion
- How Alcon leverages its global presence to expand the adoption of its advanced IOLs in key markets will be crucial for sustained growth.